Image pharmaphorum Editor News UK drugs regulator consults on 'no deal' Brexit arrangements Despite the government insisting that Brexit will have no negative fallout, the UK's drugs regulator is consulting on whether it can become a standalone body with no links to European count News Tech firms treat young, fit patients, instead of those in ne... The UK’s top GP is due to refute accusations that doctors are ‘technophobic dinosaurs’. News Lilly unveils promising data from dual-action diabetes drug Eli Lilly’s investigational diabetes drug has shown early promise as a possible aid to overcoming obesity in trial results announced this week. News Recardio ceases UK drug trials, blaming Brexit Medical research firm Recardio has ceased all of its drug trials in the UK over concerns about Brexit. Load more results
News UK drugs regulator consults on 'no deal' Brexit arrangements Despite the government insisting that Brexit will have no negative fallout, the UK's drugs regulator is consulting on whether it can become a standalone body with no links to European count
News Tech firms treat young, fit patients, instead of those in ne... The UK’s top GP is due to refute accusations that doctors are ‘technophobic dinosaurs’.
News Lilly unveils promising data from dual-action diabetes drug Eli Lilly’s investigational diabetes drug has shown early promise as a possible aid to overcoming obesity in trial results announced this week.
News Recardio ceases UK drug trials, blaming Brexit Medical research firm Recardio has ceased all of its drug trials in the UK over concerns about Brexit.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
